Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

fludarabine phosphate 36Whole-Body Irradiation 30Cyclophosphamide 30Mycophenolic Acid 28Azacitidine 27Tacrolimus 25Peripheral Blood Stem Cell Transplantation 24Busulfan 22Methotrexate 15Cyclosporine 15Antilymphocyte Serum 14Decitabine 11Cytarabine 11Melphalan 10fludarabine 9Radiotherapy 8Filgrastim 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Cord Blood Stem Cell Transplantation 7thymoglobulin 6Sirolimus 6Rituximab 6Cyclosporins 6Clofarabine 6venetoclax 5merphos 5Sorafenib 4Lenalidomide 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Chronic × lintuzumab × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡